Modality
ASO
MOA
BiTE
Target
JAK2
Pathway
mTOR
CFCKD
Development Pipeline
Preclinical
Nov 2025
PreclinicalCurrent
NCT08249168
2,584 pts·CKD
2025-11→TBD·Terminated
2,584 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Preclinical
Termina…
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08249168 | Preclinical | CKD | Terminated | 2584 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 |